New oral drug shows promise against deadly lassa fever in west africa trial
Disease control
Ongoing
This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever, a serious viral illness common in West Africa. About 135 hospitalized adults will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is t…
Phase: PHASE2 • Sponsor: Arisan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC